Navigation Links
Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
Date:9/2/2008

LAUSANNE, Switzerland, September 2 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced the signature of a research project with the Ecole Polytechnique Federale de Lausanne (EPFL), aimed at the identification of novel small molecules and peptides that interfere with pathways controlling cell fate specification. The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells.

Following the signature of an EPFL-Debiopharm partnership on February 12, this first joint research project will be performed under the supervision of Dr. Freddy Radtke, Associate Professor at the Swiss Institute for Experimental Cancer Research (ISREC) and Dr. Gerardo Turcatti, MER, Director of the Biomolecular Screening Facility (BSF), two groups at the EPFL. Debio 0826 will benefit from the multiple molecular and genetic tools generated by Dr. Radtke's group over the past 10 years, as well as the expertise of Dr. Turcatti in the molecular screening field.

"Targeting pathways controlling cell fate specification could generate innovative anti-cancer drugs with anti-tumoural, anti-metastatic and anti-angiogenic properties to treat tumours that are currently resistant to standard therapies," said Kamel Besseghir, CEO of Debiopharm S.A.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ), a ... will present an overview of the company at the 13th annual ... Waldorf Astoria Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern ... days and may be accessed at www.wafergen.com . ...
... Ill., Feb. 2, 2011 Hospira, Inc. (NYSE: ... company, today reported results for the fourth quarter and full ... 2010, net sales were $992 million, and adjusted* diluted earnings ... $3.9 billion, and adjusted* diluted earnings per share were $3.31. ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2Hospira Reports Fourth-Quarter and Full-Year 2010 Results 2Hospira Reports Fourth-Quarter and Full-Year 2010 Results 3Hospira Reports Fourth-Quarter and Full-Year 2010 Results 4Hospira Reports Fourth-Quarter and Full-Year 2010 Results 5Hospira Reports Fourth-Quarter and Full-Year 2010 Results 6Hospira Reports Fourth-Quarter and Full-Year 2010 Results 7Hospira Reports Fourth-Quarter and Full-Year 2010 Results 8Hospira Reports Fourth-Quarter and Full-Year 2010 Results 9Hospira Reports Fourth-Quarter and Full-Year 2010 Results 10Hospira Reports Fourth-Quarter and Full-Year 2010 Results 11Hospira Reports Fourth-Quarter and Full-Year 2010 Results 12Hospira Reports Fourth-Quarter and Full-Year 2010 Results 13Hospira Reports Fourth-Quarter and Full-Year 2010 Results 14Hospira Reports Fourth-Quarter and Full-Year 2010 Results 15Hospira Reports Fourth-Quarter and Full-Year 2010 Results 16Hospira Reports Fourth-Quarter and Full-Year 2010 Results 17Hospira Reports Fourth-Quarter and Full-Year 2010 Results 18Hospira Reports Fourth-Quarter and Full-Year 2010 Results 19
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... workers has suggested that the workplace may play// an important ... current study examined the role of occupational workplace and the ... physical activity and irregular food intake are some of the ... seeing a rise in the occurrence of some of the ...
... In a unique initiative a railway station – Ongole town ... announcement system to not only broadcast arrival and departures of ... the need for safe sex. Andhra Pradesh in India has ... 50-year-old porter "The current generation is racing towards HIV/AIDS like ...
... whose mothers during pregnancy consumed// low-mercury fish couple of ... those mothers who did not. ,Conversely it ... mercury content lowered the intelligence score. ,The study ... intake of their mothers during pregnancy. ,Data revealed ...
... end-stage lung cancer who were given Tarceva lived longer than ... common cancer occurring both in men and women. Two studies ... from all over the world. ,The first study was ... conducted his study in 482 patients. The study was done ...
... of sleeping less may be due to other reasons// than age ... that had been associated with increased age for the elderly population ... findings of the research show that there may be other factors ... the geriatric people. ,The research findings point to five ...
... effective in detecting blocked// carotid artery that may increase ... Virginia Commonwealth University School of Dentistry have reported that ... health of the patient can show some cases of ... patient. ,The dentists to observe the entire ...
Cached Medicine News:Health News:Drug Tarceva for End-stage Lung cancer 2
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... Catheter system is a technically ... external CSF drainage which reduces ... tube surfaces. Treated with the ... it reduces the potential for ...
Cruchfield Skull Traction Tong, small pattern....
Medicine Products: